John Saito, MD
Pediatric Pulmonology · Fountain Valley, CANPI 1851352678
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.8% of the total across 275 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by GSK at 25.2% of the total. Among pediatric pulmonology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 275 payments — averaging $28.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- Regeneron Healthcare Solutions, Inc.$2K
- AstraZeneca$1K
- Jazz Pharmaceuticals Inc.$790
- Lilly USA, LLC$368
- Avadel CNS Pharmaceuticals, LLC$201
- plus $2K from 21 others
What the payments were for
- Speaking & faculty fees$1502%
- Travel & lodging$60%
- Food & beverage$7,44996%
- Education$1702%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 89 | $1,958 |
| Regeneron Healthcare Solutions, Inc. | 48 | $1,773 |
| AstraZeneca | 41 | $1,131 |
| Jazz Pharmaceuticals Inc. | 25 | $790 |
| Lilly USA, LLC | 9 | $368 |
| Avadel CNS Pharmaceuticals, LLC | 10 | $201 |
| Merz North America, Inc. | 1 | $200 |
| Boehringer Ingelheim | 8 | $157 |
| Galderma Laboratories, L.p. | 1 | $150 |
| Amgen | 5 | $130 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $120 |
| Viatris Specialty LLC | 4 | $110 |
| Sanofi | 4 | $93 |
| AbbVie | 4 | $77 |
| Philips North America LLC | 4 | $73 |
| Electromed, Inc. | 4 | $72 |
| Mylan Specialty L.p. | 3 | $65 |
| Axsome Therapeutics, Inc. | 2 | $61 |
| Harmony Biosciences LLC | 2 | $56 |
| Inspire Medical Systems, Inc. | 2 | $41 |
| Merck | 1 | $27 |
| Pulmonx Corporation | 1 | $24 |
| Genentech USA, Inc. | 1 | $23 |
| Grifols USA, LLC | 1 | $22 |
| Optinose US, Inc. | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Resmed Corp | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,775 in reported general payments places this provider in the 90th percentile of 99 pediatric pulmonology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 180 | $132,755 |
| Breo ElliptaFluticasone/Vilanterol | 193 | $82,231 |
| Dupixent PenDupilumab | 18 | $68,499 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 81 | $53,899 |
| Dupixent SyringeDupilumab | 13 | $46,754 |
| NucalaMepolizumab | 13 | $44,455 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 820 | $26,904 |
| Incruse ElliptaUmeclidinium Bromide | 70 | $25,121 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 44 | $21,383 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 51 | $20,270 |
| Spiriva RespimatTiotropium Bromide | 33 | $18,813 |
| Ventolin HfaAlbuterol Sulfate | 216 | $13,236 |
| Fluticasone-VilanterolFluticasone/Vilanterol | 38 | $13,157 |
| Spiriva HandihalerTiotropium Bromide | 20 | $10,095 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $8,136 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Incruse Ellipta, Anoro Ellipta | $1,958 | $292,698473 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Airsupra | $1,131 | $64,271110 claims |
| Boehringer IngelheimCombivent Respimat, Spiriva Respimat | $157 | $40,19677 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 99 pediatric pulmonology providers in California.
Other pediatric pulmonology in Fountain Valley
- Zacharia RedaFountain Valley$1K
- Sande OkeloLos Angeles$146K
- Rakesh BhattacharjeeSan Diego$72K
- Carlos MillaPalo Alto$65K
- Terry RobinsonPalo Alto$23K
- Sudhakar ReddivalamMadera$14K
- Marilynn ChanSan Diego$11K
- Lauro RobertoFresno$10K
- Filomena Hazel VillaMadera$8K
- Richard MossPalo Alto$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.